Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rainer K. Reinscheid has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Stefan Schulz

    Institute of Pharmacology and Toxicology, Friedrich-Schiller University, Jena, Germany

    2 shared publications
  • Annika Lüttjohann

    Institute of Physiology I, Westfälische-Wilhelms-University, Münster, Germany

    1 shared publication
  • Celia Garau

    Department of Pharmaceutical Sciences, University of California Irvine, Irvine, CA 92617, USA

    1 shared publication
  • Chiara Ruzza

    Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy; LTTA Laboratory for Advanced Therapies, Technopole of Ferrara, Ferrara, Italy

    1 shared publication
  • Fabrizio Mafessoni

    Max-Planck-Institute for Evolutionary Anthropology, Leipzig, Germany

    1 shared publication
  • Girolamo' Calo

    Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy

    1 shared publication

Latest Publications

  • Open Access

    Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus

    by Celia Garau, Xiaobin Liu, Girolamo' Calo, Stefan Schulz, Rainer K. Reinscheid


  • Open Access

    Neuropeptide S-Mediated Modulation of Prepulse Inhibition Depends on Age, Gender, Stimulus-Timing, and Attention

    by Wei Si, Xiaobin Liu, Hans-Christian Pape, Rainer K. Reinscheid

    Conflicting reports about the role of neuropeptide S (NPS) in animal models of psychotic-like behavior and inconsistent results from human genetic studies seeking potential associations with schizophrenia prompted us to reevaluate the effects of NPS in the prepulse inhibition (PPI) paradigm in mice. Careful examination of NPS receptor (NPSR1) knockout mice at different ages revealed that PPI deficits are only expressed in young male knockout animals (<12 weeks of age), that can be replicated in NPS precursor knockout mice and appear strain-independent, but are absent in female mice. PPI deficits can be aggravated by MK-801 and alleviated by clozapine. Importantly, treatment of wildtype mice with a centrally-active NPSR1 antagonist was able to mimic PPI deficits. PPI impairment in young male NPSR1 and NPS knockout mice may be caused by attentional deficits that are enhanced by increasing interstimulus intervals. Our data reveal a substantial NPS-dependent developmental influence on PPI performance and confirm a significant role of attentional processes for sensory-motor gating. Through its influence on attention and arousal, NPS appears to positively modulate PPI in young animals, whereas compensatory mechanisms may alleviate NPS-dependent deficits in older mice.


  • Open Access

    Pharmacology, Physiology and Genetics of the Neuropeptide S System

    by Rainer K. Reinscheid, Chiara Ruzza

    The Neuropeptide S (NPS) system is a rather ‘young’ transmitter system that was discovered and functionally described less than 20 years ago. This review highlights the progress that has been made in elucidating its pharmacology, anatomical distribution, and functional involvement in a variety of physiological effects, including behavior and immune functions. Early on, genetic variations of the human NPS receptor (NPSR1) have attracted attention and we summarize current hypotheses of genetic linkage with disease and human behaviors. Finally, we review the therapeutic potential of future drugs modulating NPS signaling. This review serves as an introduction to the broad collection of original research papers and reviews from experts in the field that are presented in this Special Issue.


  • Neandertal introgression and accumulation of hypomorphic mutations in the neuropeptide S (NPS) system promote attenuated functionality

    by Rainer K. Reinscheid, Fabrizio Mafessoni, Annika Lüttjohann, Kay Jüngling, Hans-Christian Pape, Stefan Schulz


  • The History of N/OFQ and the NOP Receptor

    by Rainer K. Reinscheid, Olivier Civelli

    The discovery of nociceptin/orphanin FQ (N/OFQ) marks the genuine start of the reverse pharmacology era, when systematic hunting for ligands of orphan receptors began. The choice of this particular target was no coincidence as the orphan receptor ORL-1 displayed high similarity to known opioid receptors, and thus its elusive ligand held promise to find more than a ligand but a missing opioid peptide. N/OFQ indeed turned out to belong to the opioid peptide family, but with significant pharmacological and functional distinctions. The quest for understanding N/OFQ’s physiological functions has produced some novel insights into stress regulation and many other body functions but is still ongoing almost 25 years after its discovery. This chapter highlights the early steps of orphan receptor research and some of the protagonists who helped to advance the field.